Glenmark Pharmaceuticals has informed about press release titled ‘Data on Glenmark Pharmaceuticals GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody in Development for the Treatment of Moderate-to-Severe Atopic Dermatitis, to be Presented at the Fall Clinical Dermatology Conference.’
The above information is a part of company’s filings submitted to BSE.